Featured Research

from universities, journals, and other organizations

Patients Respond Well To New Minimally Invasive Treatment For Kidney Tumors

Date:
December 3, 2007
Source:
Lifespan
Summary:
A new study confirms the success of a newer minimally invasive technique that uses heat to destroy kidney tumors. After reviewing the outcomes of 143 solid kidney masses treated with radiofrequency ablation (RFA) over a nine-year period at Rhode Island Hospital, researchers report that 137 of 143 tumors (96%) were successfully treated.

A new study by researchers at Rhode Island Hospital confirms the success of a newer minimally invasive technique that uses heat to destroy kidney tumors.

After reviewing the outcomes of 143 solid kidney masses treated with radiofrequency ablation (RFA) over a nine-year period at Rhode Island Hospital, William Mayo-Smith, M.D., director of computed tomography at Rhode Island Hospital, and colleagues report that 137 of 143 tumors (96%) were successfully treated.

A single treatment session was effective for 123 tumors, two sessions were required for 12 tumors and three sessions were required for two tumors. Most patients in the study were in their mid-seventies, which is not uncommon, according to Mayo-Smith, since kidney tumors tend to strike the elderly. Twenty patients in the study had only one kidney due to prior surgery.

“This new minimally invasive technique appears to be an acceptable alternative to surgery in high risk patients,” said Mayo-Smith, who’s also a professor of diagnostic imaging at The Warren Alpert Medical School of Brown University. “The technique is exciting because patients are able to go home the same day of the procedure and do not require general anesthesia.”

During RFA, a very thin needle electrode is inserted into the tumor under the guidance of computed tomography (CT). The electrode is equipped to deliver high frequency radio waves that create intense heat, killing cancerous cells. The heat also closes up small blood vessels, minimizing the risk of bleeding.

More than 700 patients have undergone radiofrequency ablation at Rhode Island Hospital. To date, this is the largest known study reporting the results of RFA in treating kidney tumors.

Co-authors were Todd Schirmang, M.D., Damian Dupuy, M.D, and John Cronan, M.D., all of Rhode Island Hospital and Alpert Medical School.


Story Source:

The above story is based on materials provided by Lifespan. Note: Materials may be edited for content and length.


Cite This Page:

Lifespan. "Patients Respond Well To New Minimally Invasive Treatment For Kidney Tumors." ScienceDaily. ScienceDaily, 3 December 2007. <www.sciencedaily.com/releases/2007/11/071129201810.htm>.
Lifespan. (2007, December 3). Patients Respond Well To New Minimally Invasive Treatment For Kidney Tumors. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2007/11/071129201810.htm
Lifespan. "Patients Respond Well To New Minimally Invasive Treatment For Kidney Tumors." ScienceDaily. www.sciencedaily.com/releases/2007/11/071129201810.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins